Keywords: Bayer, Xarelto, UK, NICE, DVT, Pulmonary embolism, Cost effectiveness
UK NICE asks Bayer for Xarelto cost-effectiveness data
Article | 13 March 2012
UK health care price watchdog the National Institute for Health and Clinical Excellence (NICE), which is currently reviewing Xarelto (rivaroxaban) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
